Solomon Moshkevich Sells 3,000 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00. Following the transaction, the insider owned 134,643 shares of the company’s stock, valued at $36,744,074.70. This represents a 2.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $218.43, for a total value of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total value of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total value of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The shares were sold at an average price of $204.10, for a total value of $445,346.20.

Natera Trading Down 0.9%

Natera stock opened at $281.27 on Wednesday. The firm has a market cap of $40.28 billion, a PE ratio of -172.56 and a beta of 1.51. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The stock’s 50 day simple moving average is $223.00 and its two-hundred day simple moving average is $218.03.

Institutional Trading of Natera

Several large investors have recently made changes to their positions in NTRA. Reflection Asset Management acquired a new stake in Natera during the 4th quarter worth $29,000. Palladiem LLC purchased a new position in shares of Natera in the fourth quarter worth about $31,000. Horizon Investments LLC purchased a new position in shares of Natera in the third quarter worth about $32,000. International Assets Investment Management LLC boosted its position in Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the last quarter. Finally, Bank of Jackson Hole Trust grew its stake in Natera by 103.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 83 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on NTRA shares. UBS Group set a $260.00 price objective on shares of Natera in a research report on Wednesday, June 24th. William Blair began coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Sanford C. Bernstein started coverage on Natera in a report on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target for the company. Guggenheim boosted their price objective on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $262.00.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.